SOBI Receives Complete Response Letter From FDA For NASP

Swedish Orphan Biovitrum AB (publ) OMXSTO:SOBI:

• SOBI RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR NASP (NANOENCAPSULATED SIROLIMUS PLUS PEGADRICASE)

• SWEDISH ORPHAN BIOVITRUM - FDA REQUESTS ADDITIONAL MANUFACTURING DATA AND FACILITY DEFICIENCIES ADDRESSED FOR NASP

• SWEDISH ORPHAN BIOVITRUM - SOBI TO MEET WITH FDA TO DISCUSS NASP RESUBMISSION